BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11262212)

  • 21. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Chan HL; Wang H; Niu J; Chim AM; Sung JJ
    Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy].
    Wang L; Yan J; Zhang ZH; Wang JB; Du YZ; Li XY; Wang YZ
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):585-8. PubMed ID: 15504286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patients.
    Lu L; Zhang HY; Yueng YH; Cheung KF; Luk JM; Wang FS; Lau GK
    J Viral Hepat; 2009 Feb; 16(2):104-12. PubMed ID: 19175882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
    Lu H; Ma LX; Xu WS; Zhang HY; Yu LJ; Duan HY
    Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
    Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
    J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.
    Sun LJ; Yu JW; Zhao YH; Kang P; Li SC
    J Gastroenterol Hepatol; 2010 Mar; 25(3):583-90. PubMed ID: 19968744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
    Woo HY; Park H; Kim BI; Jeon WK; Cho YK; Kim YJ
    Antivir Ther; 2007; 12(1):7-13. PubMed ID: 17503742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
    Chien RN; Liaw YF
    Antivir Ther; 2006; 11(7):947-52. PubMed ID: 17302259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.
    Hacker HJ; Zhang W; Tokus M; Bock T; Schröder CH
    Ann N Y Acad Sci; 2004 Jun; 1022():271-81. PubMed ID: 15251972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy.
    Puchhammer-Stöckl E; Mandl CW; Kletzmayr J; Holzmann H; Hofmann A; Aberle SW; Heinz FX; Watschinger B; Hofmann H
    J Infect Dis; 2000 Jun; 181(6):2063-6. PubMed ID: 10837194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
    Hatakeyama T; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Kawakami Y; Fujimoto Y; Ochi H; Abe H; Maekawa T; Kawakami H; Yatsuji H; Aisaka Y; Kohno H; Aimitsu S; Chayama K
    Hepatology; 2007 May; 45(5):1179-86. PubMed ID: 17465002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Correlation of HBV DNA level and viral breakthrough during lamivudine therapy for chronic hepatitis B].
    Park HS; Lee DH; Heo J; Kim GH; Kang DH; Song GA; Cho M
    Korean J Hepatol; 2006 Jun; 12(2):173-83. PubMed ID: 16804342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.